It has recently been proposed that the increased reinforcing properties of cocaine and ecstasy observed in rats with a genetic deletion of serotonin transporters are the result of a reduction in the psychostimulant-induced release of serotonin. Here we provide the neurochemical evidence in favor of this hypothesis and show that changes in synaptic levels of dopamine or noradrenaline are not very likely to play an important role in the previously reported enhanced psychostimulant intake of these serotonin transporter knockout rats. The results may very well explain why human subjects displaying a reduced expression of serotonin transporters have an increased risk to develop addiction.
Introduction
Animal studies have shown that a genetic deletion of serotonin transporters (SERT) greatly enhances the reinforcing properties of cocaine (COC) and ecstasy (MDMA), as well as the acquisition of their intake (Homberg et al., 2008; Oakly et al., 2014) . These studies performed in SERT knockout (KO) rats are in line with human studies showing that a reduction in SERT activity predicts an increased psychostimulant intake (Gerra et al., 2007; MartinSantos et al., 2010) . Because of the lack of plasmalemmal (c-f) In spite of a seemingly small difference in basal accumbal dopamine (DA) and noradrenaline (NA) levels, neither these baseline monoamine levels nor the COC-induced increases of accumbal dopamine (DA) and noradrenaline (NA) significantly differed between SERT KO and SERT WT rats (n.s. =non-significant change). (g) Maximum COCinduced increase of extracellular accumbal serotonin (5-HT) in (SERT KO) rats that lack serotonin transporters (Student's t-test: n Po0.05). Open symbols (O/□) represent a significant increase relative to baseline (one sample t-test vs. 100%). Data are expressed as mean7s.e.m. (n =5 rats/group). serotonin transporters (Homberg et al., 2007) , SERT KO animals are not only marked by increased extracellular levels of serotonin ( Figures 1a and 2a) , but also by a reduced amount of releasable serotonin inside their cells (Kalueff et al., 2010) . Using 5,7-dihydroxytryptamine-(5,7-DHT)-treated rats, it has elegantly been shown that a sustained increase in the baseline extracellular central levels of serotonin results in a decreased, instead of an increased, intake of psychostimulants (Bradbury et al., 2014) . In a recent self-administration study by Oakly et al. (2014) it was, therefore, proposed that a reduced evoked release of serotonin underlies the observed increased reinforcing properties of COC and MDMA in SERT KO rats. Here we provide the missing neurochemical evidence in favor of their hypothesis and show that changes in synaptic levels of dopamine or noradrenaline are not likely to play an important role in the enhanced psychostimulant intake reported in individuals lacking plasmalemmal serotonin transporters.
Experimental procedures
SERT KO rats (Slc6a4 1Hubr ) were generated by target-selected ENUinduced mutagenesis (for detailed description, see Homberg et al. (2007) ). Briefly, high-throughput sequencing from mutagenized rats revealed a functional ENU-induced premature stop codon in exon 3 of the SERT gene of a female Wistar rat. This heterozygous mutant animal was outcrossed for at least eight generations to a Wistar background. Homozygous SERT KO rats were generated by crossing heterozygous SERT KO animals and genotyping was performed at the age of 21 days (primer sequences can be found in Homberg et al. (2007) ). All rats were individually housed in our standard microdialysis cages (25 Â 25 Â 35 cm 3 ) under controlled experimental conditions (12/12 h light/dark cycle, 2171 1C, 60% relative humidity, food and water were available ad libitum). Adult male SERT KO rats and their wild type (WT) counterparts were intraperitoneally injected with saline (volume: 1 ml/kg) and cocaine (dose: 10 mg/ kg) and the synaptic levels of serotonin, dopamine, and noradrenaline were measured in the nucleus accumbens shell and the ventral hippocampus according to previously described microdialysis procedures (Homberg et al., 2007; Verheij et al., 2008) . The nucleus accumbens and the hippocampus were chosen because they play an important role in mediating reward (Carlezon and Thomas, 2009; Devenport et al., 1981) . Statistics are described in the figure legends. All experiments were in agreement with institutional, national, and international laws and guidelines for animal care and welfare.
Results
COC is known to increase the extracellular monoamine levels by blocking plasmalemmal monoamine transporters (Ritz et al., 1987) . As expected, the COC-induced serotonin increase in both the nucleus accumbens shell and the ventral hippocampus is smaller in SERT KO than SERT WT rats (Figures 1b and 2b) . Despite suggestions that the variation in psychostimulant intake between these two rat types is due to (serotonin-induced) changes in synaptic dopamine or noradrenaline (Nonkes et al., 2011; Oakly et al., 2014) , the observed genotype differences in the baseline levels of serotonin (Figures 1a and 2a) were not accompanied by genotype differences in the baseline levels of the two other monoamines (dopamine : Figures 1c and 2c ; noradrenaline: Figures 1e and 2e ). In addition, SERT KO rats and their WT counterparts were found not to differ in both the electrically-evoked central release of dopamine and noradrenaline (Homberg et al., 2007) as well as the COC-induced increase of the extracellular levels of these two monoamines in either the nucleus accumbens (Figure 1d and f) or the hippocampus (Figure 2d and f) . Finally, neither the central expression of plasmalemmal dopamine and noradrenaline transporters, nor the uptake by these two transporters differs between SERT KO and SERT WT rats (Homberg et al., 2007) . These data indicate that both the genotype-specific central serotonin response to COC (Figures 1b and 2b) and the previously reported individual differences in the reinforcing effects of this drug (Homberg et al., 2008) are most likely not due to (COC-induced) changes in dopaminergic or noradrenergic neurons. Although these individual differences in the reinforcing effects between SERT KO and SERT WT rats have been found after administration of the same dose of COC that was used in the present study (see Homberg et al. (2008) ), our study does not fully exclude the possibility that COC-induced individual differences in central dopamine and noradrenaline levels may potentially contribute to genotype variation in the reinforcing effects between the two rat types following the administration of a different dose of the psychostimulant.
Discussion
Remarkably, COC significantly increased the extracellular levels of serotonin in SERT KO rats (Figures 1g and 2g) . The finding that COC increases the extracellular levels of serotonin in rats lacking serotonin transporters may very well be explained by our previously reported hypothesis that COC, like MDMA, releases neurotransmitters from storage vesicles (Verheij and Cools, 2011; Verheij et al., 2008 Verheij et al., , 2013 . The previously reported finding that the electrically-evoked release of central serotonin is smaller in SERT KO than SERT WT rats (Homberg et al., 2007) indicates that the contribution of (vesicular) release to the COC-induced extracellular serotonin increase is also smaller in SERT KO than that in SERT WT rats. Our previous and present data, therefore, underline the notion of Oakly et al. (2014) that a reduction in the evoked (vesicular) release of serotonin may have contributed to the enhanced acquisition of psychostimulant intake observed in individuals with a genetic deletion of plasmalemmal serotonin transporters. Given that reduced binding of serotonin to its receptors in the nucleus accumbens prevents both the rewarding effects of cocaine and the behavioral sensitization to this drug (Filip and Cunningham, 2002; Przegalinski et al., 2002; Zayara et al., 2011) , we hypothesize that a decrease of COCinduced serotonin release in brain regions other than the nucleus accumbens (e.g., the hippocampus) mediates the enhanced cocaine self-administration of SERT KO rats. Additional studies are under way.
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